Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs KKR & Co Inc — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.38 (market cap $4.03B), while KKR & Co Inc trades at $86.26 (market cap $76.84B). The key difference: KKR & Co Inc is far larger — about 19.1× Indivior Pharmaceuticals Inc. Common Stock's market cap, and KKR & Co Inc pays a 0.91% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and KKR & Co Inc for 67 Days on average.
| INDV | KKR | |
|---|---|---|
Market Cap | $4.03B | $76.84B |
Volume | 2,781,171 | 12,064,615 |
Sector | Health | Financials |
52-Week High | $41.83 | $142.75 |
52-Week Low | $24.09 | $83.88 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $4.32B | -$604.63M |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KKR trades at $87.16, down 4.75% over 24 hours, with a bearish technical signal and neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results pending. Revenue for 2025 was $19.21 billion, with a net income margin of 14.97%. Recent news highlights strategic investments and joint ventures, including a partnership with Thomson Reuters and a new equipment finance platform.
The outlook for KKR is supported by strong analyst consensus, with 24 buy ratings and a price target of $123.20, indicating significant upside. However, risks include volatile cash flows, high debt levels, and market sensitivity. The stock's current valuation metrics, such as a P/E of 27.35, suggest it is fairly priced relative to peers, but execution on monetization and growth initiatives will be key drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
